Abstract 3399: Tumor organoid based drug sensitivity testing in ovarian cancer identifies exceptional responders to targeted therapies
Amanda M. Prechtl(Precision for Medicine (United States)), Carla Grandori(Precision for Medicine (United States)), Samantha Velazquez(Precision for Medicine (United States)), Hallie A. Swan(Precision for Medicine (United States)), Heidi J. Gray(Seattle Cancer Care Alliance), Kalyan Banda(University of Washington), Barbara A. Goff(University of Washington), Payel Chatterjee(Precision for Medicine (United States)), Rachele Rosati(Precision for Medicine (United States)), Brady Bernard(Providence Portland Medical Center), Siddhartha Mukherjee(NewYork–Presbyterian Hospital), Elizabeth M. Swisher(University of Washington), Grace Durenberger(Precision for Medicine (United States)), Marwah Al-Aloosi(Precision for Medicine (United States)), Christopher J. Kemp(Fred Hutch Cancer Center), Cristina Alén Cordero(Precision for Medicine (United States)), Robert L. Diaz, Lauren Appleyard(Precision for Medicine (United States))
Cited by 0
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
|Annual Review of Cell and Developmental Biology|2000|1.3k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Direct activation of TERT transcription by c-MYC
|Nature Genetics|1999|903